Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23459152 | 1.00 | KDM4E (0.52) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL20897407 | 0.93 | HTT (0.55) | NPC1HPGDRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1892032 | 0.91 | KDM4E (0.66) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1012178 | 0.91 | KDM4E (0.66) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL12310507 | 0.89 | ALDH1A1 (0.58) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3138320 | 0.88 | CTSV (0.57) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4728946 | 0.88 | CTSV (0.57) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4469125 | 0.87 | SMN1; SMN2 (0.52) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL874091 | 0.87 | HTT (0.55) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL159448 | 0.87 | HTT (0.55) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150317-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2024-05-09 | — | — | US | disclosed |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2022-02-03 | — | — | US | disclosed |
| CN-110629246-B | Vantanib and analogue intermediate electro-reduction preparation method thereof | 湖南大学 | 2021-03-16 | — | — | CN | disclosed |
| CN-110629246-A | Vantanib and analogue intermediate electro-reduction preparation method thereof | 湖南大学 | 2019-12-31 | — | — | CN | disclosed |
| US-20190263782-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2019-08-29 | — | — | US | disclosed |
| US-10344015-B2 | Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180118716-A1 | Chemical Process | GENZYME CORPORATION (US) | 2018-05-03 | — | — | US | disclosed |
| US-9815816-B2 | Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160185754-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | ASTRAZENECA AB (SE) | 2016-06-30 | — | — | US | disclosed |
| CN-102503898-B | Chemical process for preparing quinazoline derivatives | ASTRAZENECA SWEDEN AB | 2015-03-25 | — | — | CN | disclosed |
| WO-2008053221-A2 | PROCESS FOR PREPARING INDOL- 5 -OXY- QUINAZOLINE DERIVATIVES AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| US-7329655-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| WO-2007036713-A2 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
| US-6750218-B2 | INHIBITORY ACTIVITY ON PHOSPHORYLATION OF PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | MILLENNIUMIUM PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | MATSUNO KENJI (JP) | 2003-12-11 | — | — | US | disclosed |
| US-6472391-B2 | INHIBIT PHOSPHORYLATION OF PDGF RECEPTOR TO HINDER ABNORMAL CELL GROWTH AND CELL WANDERING; TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6207667-B1 | USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | ERBB4, NPR1, PDGFRB | KDM4E 2801/4885NPC1 3452/4885HPGD 1194/4885 |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | KDM4E 2799/4885NPC1 3532/4885HPGD 1009/4885 |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDM4E 109/4885NPC1 3167/4885HPGD 1110/4885 |
| US-20240150317-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDM4E 109/4885NPC1 3167/4885HPGD 1110/4885 |
| US-20160185754-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDM4E 109/4885NPC1 3167/4885HPGD 1110/4885 |
| US-20190263782-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDM4E 109/4885NPC1 3167/4885HPGD 1110/4885 |
| US-10344015-B2 | Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDM4E 103/4885NPC1 3160/4885HPGD 1163/4885 |
| US-20180118716-A1 | Chemical Process | CYP3A4, CYP3A5, CYP3A7 | KDM4E 342/4885NPC1 2914/4885HPGD 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.